OSI to defend Teva challenge to Tarceva patents
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has challenged key US patents claiming OSI Pharmaceuticals' cancer drug Tarceva (erlotinib) as it seeks to market a generic version. Its ANDA contains a paragraph IV certification stating that certain Orange Book-listed patents are invalid and/or unenforceable or will not be infringed. OSI says that it plans to file a patent infringement suit.